ReviewPublished 25 September 2026CLDN18 and FGFR2 splicing variants are emerging tumor-associated antigens for cancer therapyMasuko Katoh · Masaru KatohFrontiers in Molecular Medicinedoi 10.3389/fmmed.2026.1927389
ReviewPublished 4 August 2026Beyond the hallmarks of cancer: enabling technologies reshaping cancer diagnosis, prevention, and treatmentSarfaraz K. NiaziOncology Reviewsdoi 10.3389/or.2026.1804447
Original ResearchPublished 4 May 2026Optimisation of patient-reported outcome measurement for haematological cancer patients receiving novel immunotherapies: perspectives of multi-stakeholdersEilidh M Duncan · Jhulia Salviano · Charalampia Kyriakou · Samantha Nier · Simone Oerlemans · Sam Salek · Kate Morgan · Katie JoynerFrontiers in Hematologydoi 10.3389/frhem.2026.1800304
ReviewPublished 7 January 2026To treat or not to treat: a state-of-the-art overview of smoldering multiple myelomaAyushi Garg · Srinivas DevarakondaFrontiers in Hematologydoi 10.3389/frhem.2025.1706219
